Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why? -- Ignore unavailable to you. Want to Upgrade?

To: Ron who wrote (374)	11/3/1998 8:55:00 AM
From: Douglas	Respond to of 455

Procept's PRO 2000 Gel Selected to Enter Government-Supported Clinical Trial U.S. Food and Drug Administration Allows Study to Proceed Following IND Review CAMBRIDGE, Mass.--(BW HealthWire)--Nov. 2, 1998--Procept, Inc. (Nasdaq:PRCT - news) today announced that its lead product candidate, PRO 2000 Gel, was selected for safety testing in a human clinical trial supported by the National Institute of Allergy and Infectious Diseases (NIAID), a unit of the National Institutes of Health (NIH). The United States Food and Drug Administration (FDA) permitted the trial to proceed following review of an Investigational New Drug (IND) application filed by Procept. The study, which will involve women in the United States and South Africa, is scheduled to begin in early 1999. PRO 2000 Gel is being developed as a topical microbicide for the prevention of sexually transmitted diseases (STDs), including AIDS. It is designed to be applied vaginally before sexual intercourse. In laboratory studies, PRO 2000 Gel was shown to be active against the human immunodeficiency virus (HIV, the cause of AIDS) as well as herpes simplex virus type 2 (HSV-2) and Chlamydia trachomatis, two other common STD pathogens. Furthermore, intravaginally applied PRO 2000 Gel was shown to prevent vaginal HSV-2 infection in mice. Two human Phase I clinical trials, conducted last year in Europe, found that daily doses of PRO 2000 Gel were safe and well tolerated in healthy, sexually abstinent women. One of these studies was supported by the British Medical Research Council (MRC). The NIAID-supported clinical trial is designed to evaluate the safety and acceptability of PRO 2000 Gel in healthy, sexually active women, and in HIV-infected women in the United States and South Africa. The trial will be conducted by the HIV Network for Prevention Trials (HIVNET), an organization established by NIAID in 1993 to evaluate the safety and effectiveness of different approaches to AIDS prevention, including vaccines, behavioral interventions, and topical microbicides. HIVNET currently includes eleven domestic and eleven international field sites, as well as supporting infrastructure. ''We are excited that the NIH is supporting the continued clinical development of PRO 2000 Gel'' said John Dee, President and Chief Executive Officer of Procept. ''The upcoming study represents the second major step on the clinical path leading to product approval. We believe that Procept is well positioned to make a timely contribution to the urgent demand for new methods to prevent HIV infection and other STDs. As a recent article in the respected trade publication Scrip noted, PRO 2000 Gel is 'the most advanced [new] microbicide in commercial development.''' Large Potential Market Seen for Topical Microbicides A recent study commissioned by the European Union found that a large potential market exists for vaginal microbicides capable of preventing HIV infection and other STDs. For example, the potential market in Brazil alone was estimated to approach $1 billion per year. The results of the survey, presented at the 12th World AIDS Conference in Geneva last July, showed that many women in both developed and developing countries would find a female-controlled prevention product ''very useful'', and would be willing to spend significantly more than the price of a condom for it. Interestingly, most women favored a ''dual-use'' product that had both antimicrobial and contraceptive properties. PRO 2000 Gel has also been shown to be contraceptive in rabbits. Procept, Inc., located in Cambridge, MA, is a biopharmaceutical company currently engaged in the development of novel drugs with a focus on anti-infectives and immunosuppressants. Its lead product, PRO 2000 Gel, is being developed as a female-controlled topical microbicide for the prevention of HIV infection and certain other sexually transmitted diseases. Procept also plans to out-license its early-stage immunosuppressive research and to in-license high-potential drug development compounds.